Answers are grounded in this paper and cite their sources.
To illustrate the diagnostic pitfalls and key histopathologic clues in a rare case that the tumor was anatomically confined to the uterus with superficial myometrial invasion, which would correspond to FIGO 2009 Stage IA; however, given its aggressive histology (dedifferentiated carcinoma) and p53abn molecular profile, it was restaged as FIGO 2023 Stage IIC mp53abn. A 33-year-old woman presented with 7 years of intermittent postcoital bleeding. Cervical cytology showed high-grade squamous intraepithelial lesion despite negative HPV testing. Colposcopic biopsies of the cervix and endocervical canal revealed poorly differentiated carcinoma; immunohistochemistry favored high grade neuroendocrine carcinoma with possible adenocarcinoma admixture, leading to a pre-operative diagnosis of FIGO 2018 Stage IB2 cervical neuroendocrine carcinoma. Laparoscopic radical hysterectomy with pelvic lymphadenectomy was performed. Definitive pathologic examination of the surgical specimen re-classified the tumor as dedifferentiated endometrial carcinoma, FIGO 2023 stage IIC mp53abn. This case underscores the importance of comprehensive tissue sampling and judicious use of immunohistochemistry to avoid misclassifying uterine dedifferentiated carcinoma as cervical neuroendocrine malignancy, thereby ensuring appropriate surgical staging and adjuvant management.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: